enGene Therapeutics Inc. (ENGN)
NASDAQ: ENGN · Real-Time Price · USD
2.410
+0.130 (5.70%)
At close: Nov 13, 2026, 4:00 PM EST
2.319
-0.091 (-3.78%)
After-hours: Nov 13, 2026, 7:58 PM EST
enGene Therapeutics Stock Forecast
Stock Price Forecast
According to 9 analysts polled by S&P Global, enGene Therapeutics stock has a consensus rating of "Buy" and an average price target of $4.29. The average 1-year stock price forecast is 77.84% higher than the current stock price, while the lowest is $2.00 (-17.01%) and the highest is $6.00 (+148.96%).
Price Target: $4.29 (+77.84%)
Analyst Consensus: Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for enGene Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jun '26 | Jul '26 | Aug '26 | Sep '26 | Oct '26 | Nov '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 4 |
| Buy | 1 | 1 | 1 | 1 | 1 | 2 |
| Hold | 6 | 6 | 6 | 6 | 6 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 1 | 1 | 1 | 1 | 0 | 0 |
| Total | 10 | 10 | 10 | 10 | 9 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Guggenheim | Guggenheim | Hold Maintains n/a | Hold | Maintains | n/a | n/a | Nov 13, 2026 |
| Leerink Partners | Leerink Partners | Buy Upgrades $5 | Buy | Upgrades | $5 | +107.47% | Nov 13, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $4 | Buy | Reiterates | $4 | +65.98% | Nov 12, 2026 |
| Piper Sandler | Piper Sandler | Buy Upgrades $4 | Buy | Upgrades | $4 | +65.98% | Nov 12, 2026 |
| Wells Fargo | Wells Fargo | Buy Upgrades $2 → $6 | Buy | Upgrades | $2 → $6 | +148.96% | Nov 12, 2026 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
4.68M
EPS This Year
-1.82
from -2.29
EPS Next Year
-1.59
from -1.82
EPS and Forward PE are based on non-GAAP adjusted numbers.